Скачать или смотреть Radiofrequency Ablation Devices Market Outlook 2031 – Growth, Trends & Future Insights!

The global radiofrequency ablation (RFA) devices market size was valued at USD 5,220.0 million in 2023 and is projected to grow from USD 5,739.5 million in 2024 to USD 12,255.8 million by 2031, exhibiting a CAGR of 11.45% during the forecast period.

The market for radiofrequency ablation devices is registering steady growth, driven by technological advancements and the increasing adoption of minimally invasive procedures. This growth is primarily fueled by the rising prevalence of conditions such as cancer, chronic pain, and heart arrhythmias, all of which are commonly treated with RFA.

Major companies operating in the radiofrequency ablation devices industry are Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Stryker Corporation, Hologic, Inc., AngioDynamics, Inc., Koninklijke Philips N.V., Smith+Nephew, Becton, Dickinson and Company, Olympus Corporation, Biotronik, Arthrex, Inc., Avanos Medical, Inc., Merit Medical Systems., and BVM MEDICAL LTD.

The demand for non-invasive treatment options has surged as cancer rates continue to rise globally, particularly for tumors in organs such as the liver, lungs, and kidneys. Similarly, RFA’s role in chronic pain management, particularly for back pain, osteoarthritis, and neck pain, is contributing to its expanding use.

The aging population further supports the need for these kinds of treatments, as more people seek alternatives to traditional surgical methods.

In April 2024, Medtronic received FDA clearance for the OsteoCool 2.0 bone tumor ablation system. The upgraded system features four internally cooled probes, allowing for more efficient and flexible treatments, including multi-level spine tumor ablations. OsteoCool 2.0 is the only system with cooled probes, ensuring predictable ablations and effective pain relief.

Unlock the full report with detailed trends, forecasts, and competitive insights here:https://www.kingsresearch.com/radiofr...